Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AZ
AZN.LSE
AZ
AstraZeneca PLC
AZN.LSE
News
·
Haleon And 2 British AI Healthcare Stocks To Watch
Mkt Cap
$196.93B
Volume
2.57M
Next Earnings
October 30th
Chart
Financials
Earnings
News
About
Insider
Filings
Haleon And 2 British AI Healthcare Stocks To Watch
America's vast AI infrastructure build is starting to look more fragile, and that matters for UK investors watching where the real value sits in artificial intelligence. Hardware projects can stall when financing or public support weakens. Software that helps doctors work faster …
finance.yahoo.com · Oct 18, 2026
AstraZeneca (LSE:AZN) Enters AI Drug Discovery Partnership In MASH And Cardiomyopathies
AstraZeneca (LSE:AZN) has signed an exclusive worldwide research collaboration with insitro focused on MASH and cardiomyopathies. The agreement will use insitro's machine learning and high throughput biology platforms to identify new therapeutic targets. insitro is eligible for s…
finance.yahoo.com · Oct 15, 2026
3 British AI Healthcare Stocks With At Least 4% Revenue Growth
Big Tech is pouring an estimated $700b into AI infrastructure this year, and global healthcare is a key proving ground for whether that spend pays off. UK investors are watching closely because hospitals, drug makers and software providers that can turn AI into real efficiency ga…
finance.yahoo.com · Oct 11, 2026
AstraZeneca (LSE:AZN) Puts AI Into Biologics Labs With New Discovery Tie Up
AstraZeneca (LSE:AZN) has launched a new AI-driven biologics discovery collaboration with Carterra, announced ahead of trading on 9 October 2026. The partnership links AstraZeneca's AI models with Carterra's high-throughput biosensor instruments to create autonomous, lab-in-the-l…
finance.yahoo.com · Oct 10, 2026
AstraZeneca (LSE:AZN) Opened A $1 Billion R&D Center In Kendall Square
AstraZeneca (LSE:AZN) has opened a new US$1b global R&D center in Kendall Square, Massachusetts, focused on multiple disease areas. The facility brings together work in oncology, cell therapy, chronic and rare diseases, and obesity under one expanded US hub. The site incorporates…
finance.yahoo.com · Oct 7, 2026
3 British AI Healthcare Stocks With Revenue Up To £61 Billion
Rising UK government bond yields have pushed up borrowing costs and sharpened the focus on where future productivity gains might come from. Artificial intelligence in healthcare offers one clear answer. It aims to cut waste, speed up diagnosis and make treatment more precise, whi…
finance.yahoo.com · Oct 3, 2026
AstraZeneca (LSE:AZN) Wins FDA Priority Review For IMFINZI In Bladder Cancer
AstraZeneca (LSE:AZN) reported that the FDA has granted Priority Review to a supplemental Biologics License Application for IMFINZI with enfortumab vedotin in muscle-invasive bladder cancer. The application targets patients who are ineligible for or decline cisplatin-based chemot…
finance.yahoo.com · Sep 30, 2026
Is AstraZeneca (LSE:AZN) Undervalued Following Its New Lung Cancer FDA Filing?
AstraZeneca (LSE:AZN) has just filed a New Drug Application with the US FDA for combining ORPATHYS and TAGRISSO in a specific form of advanced non small cell lung cancer after EGFR TKI treatment. AstraZeneca's latest oncology filings land after a choppy run for the ticker, with t…
finance.yahoo.com · Sep 30, 2026
AstraZeneca invests £1.5bn into US firm Summit for cancer drug tie-up
Drug giant AstraZeneca has invested two billion US dollars (£1.5 billion) in US pharmaceutical firm Summit Therapeutics as part of a cancer treatment research joint venture. London-listed Astra's equity investment will help speed up development of Summit's experimental drug, call…
uk.finance.yahoo.com · Sep 29, 2026
3 British AI Stocks With Revenue Up To £61 Billion
Rising UK borrowing costs, highlighted by the recent jump in 10 year gilt yields ahead of the next budget, are forcing investors to think harder about where future growth could come from. That is one reason artificial intelligence in healthcare is getting more attention. This pie…
finance.yahoo.com · Sep 24, 2026
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AZ
AZN.LSE
AstraZeneca PLC
Buy
Sell
Market
Limit
Soon
AZN.LSE
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any AZN.LSE yet.
Related Tickers
Earnings